When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.

That's why we have released our Free Precious Metals Investment Guide.

Steve E. Krognes net worth and biography

Steve Krognes Biography and Net Worth

CFO of Denali Therapeutics

Steve Krognes is our Chief Financial Officer. He is responsible for finance, investor relations, procurement, corporate communications, IT and facilities.

Steve previously worked at Genentech and Roche for twelve years. At Genentech, he served as CFO and as a member of the Executive Committee for six years, where he was responsible for finance, site services and IT. Steve also represented Genentech on the Board and Executive Committee of the California Life Science Association and served as Chairman of the Genentech Access to Care Foundation.

At Roche in Switzerland, Steve led the global Mergers & Acquisition team for more than five years. Under Steve’s leadership, the M&A team executed more than 30 transactions worldwide, including the acquisitions of Ventana Medical Systems and Genentech. Steve worked as an investment banker at Goldman Sachs in London, a management consultant at McKinsey in London, and as a venture capitalist in Stockholm.

Steve holds an M.B.A. from Harvard Business School, a B.S. in economics from the Wharton School of the University of Pennsylvania and is a Second Lieutenant in the Royal Norwegian Air Force.

What is Steve E. Krognes' net worth?: The estimated net worth of Steve E. Krognes is at least $712,482.05 as of April 1st, 2024. Mr. Krognes owns 47,341 shares of Denali Therapeutics stock worth more than $712,482 as of April 25th. This net worth approximation does not reflect any other assets that Mr. Krognes may own. Learn More about Steve E. Krognes' net worth.
How do I contact Steve E. Krognes?: The corporate mailing address for Mr. Krognes and other Denali Therapeutics executives is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. Denali Therapeutics can also be reached via phone at (615) 866-8548 and via email at [email protected]. Learn More on Steve E. Krognes' contact information.
Has Steve E. Krognes been buying or selling shares of Denali Therapeutics?: Steve E. Krognes has not been actively trading shares of Denali Therapeutics during the last quarter. Learn More on Steve E. Krognes' trading history.
Who are Denali Therapeutics' active insiders?: Denali Therapeutics' insider roster includes Carole Ho (Insider), Steve Krognes (CFO), Vicki Sato (Director), David Schenkein (Director), Alexander Schuth (COO), Marc Tessier-Lavigne (Director), and Ryan Watts (CEO). Learn More on Denali Therapeutics' active insiders.
Are insiders buying or selling shares of Denali Therapeutics?: In the last twelve months, insiders at the sold shares 31 times. They sold a total of 210,517 shares worth more than $4,491,915.99. The most recent insider tranaction occured on April, 15th when Director Vicki L Sato sold 1,666 shares worth more than $30,471.14. Insiders at Denali Therapeutics own 7.9% of the company. Learn More about insider trades at Denali Therapeutics.
Information on this page was last updated on 4/15/2024.

Steve E. Krognes Insider Trading History at Denali Therapeutics

Steve E. Krognes Buying and Selling Activity at Denali Therapeutics

Denali Therapeutics Company Overview

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Today's Range

Now: $14.96

$14.56

$15.25

50 Day Range

MA: $19.10

$15.56

$23.35

2 Week Range

Now: $14.96

$14.56

$33.31

Volume

1,140,316 shs

Average Volume

1,180,385 shs

Market Capitalization

$2.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33

The Gold Grab of the Century

From Colonial Metals | Ad